Skip to main content

Diabete Type 2

2
Pipeline Programs
6
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Chong Kun Dang Pharmaceutical
1 program
1
empagliflozin 10mgPhase 41 trial
Active Trials
NCT07365358Not Yet Recruiting200Est. Aug 2027
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
digital prosthetic interface technologyPhase 21 trial
Active Trials
NCT05656924Active Not Recruiting38Est. Dec 2027
Verona Pharma
Verona PharmaUK - London
1 program
Gel therapy after non surgical therapyN/A1 trial
Active Trials
NCT07372677Recruiting70Est. Jan 2030
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
PomJuiceN/A1 trial
Active Trials
NCT04591782Completed42Est. Dec 2021
Innovation Pharmaceuticals
1 program
Starch 1N/A1 trial
Active Trials
NCT04115657Completed12Est. Dec 2022
Rivus Pharmaceuticals
Rivus PharmaceuticalsVA - Charlottesville
1 program
HU6PHASE_21 trial
Active Trials
NCT06104358Withdrawn0Est. Mar 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Chong Kun Dang Pharmaceuticalempagliflozin 10mg
Human BioSciencesdigital prosthetic interface technology
Rivus PharmaceuticalsHU6
Verona PharmaGel therapy after non surgical therapy
Innovation PharmaceuticalsStarch 1
Angeles TherapeuticsPomJuice

Clinical Trials (6)

Total enrollment: 362 patients across 6 trials

Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Start: Mar 2026Est. completion: Aug 2027200 patients
Phase 4Not Yet Recruiting
NCT05656924Human BioSciencesdigital prosthetic interface technology

Deploying Digital Prosthetic Interface Technology and Exercise in Dysvascular Amputees

Start: Dec 2023Est. completion: Dec 202738 patients
Phase 2Active Not Recruiting

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

Start: Nov 2023Est. completion: Mar 20250
Phase 2Withdrawn
NCT07372677Verona PharmaGel therapy after non surgical therapy

Pocket-X Gel Non-surgical Periodontal Therapy

Start: Jun 2025Est. completion: Jan 203070 patients
N/ARecruiting

The Effect of Different Starches of Boba Pearls and Sugar Substitutes Used in Milk Tea on Glycaemia, Insulinaemia and Appetite Control (Pearl Study)

Start: May 2019Est. completion: Dec 202212 patients
N/ACompleted

Investigation of PJ vs. Sugar on Glucose Levels in Healthy and Prediabetic Subjects

Start: Feb 2019Est. completion: Dec 202142 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 362 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.